Daiwa Securities Reiterates Buy (1) Rating on Wuxi Biologics (2269:HK) (WXXWY)
Tweet
Share
E-mailDaiwa Securities analyst Dennis Ip reiterated a Buy (1) rating and HK$135.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).
You May Also Be Interested In
- MediaTek Inc. (2454:TT) (MDTKF) PT Raised to NT$1,250 at Credit Suisse
- Macquarie Upgrades Bangkok Dusit (BDMS:TB) (BDULF) to Outperform
- Aperam SA (APAM:NA) (APEMY) PT Raised to EUR40 at Jefferies
Create E-mail Alert Related Categories
Intl RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
